A 12-Month, Randomized, Active-controlled, Open-label Study of the Efficacy and Safety of Oral Testosterone Undecanoate in Hypogonadal Men (RE-TUne)
Phase of Trial: Phase III
Latest Information Update: 22 Mar 2018
At a glance
- Drugs Testosterone undecanoate (Primary)
- Indications Hypogonadism
- Focus Registrational; Therapeutic Use
- Acronyms RE-TUne
- Sponsors Marius Pharmaceuticals; SOV Therapeutics
- 20 Mar 2018 Planned primary completion date changed from 9 Mar 2018 to 20 Mar 2019.
- 15 Feb 2018 Planned End Date changed from 20 Jan 2019 to 30 Apr 2019.
- 15 Feb 2018 Planned primary completion date changed from 11 Feb 2018 to 9 Mar 2018.